Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product

Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont. and NEWPORT NEWS, Va., April 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE...